Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Thomas PL, Groves SM, Zhang YK, Li J, Gonzalez-Ericsson P, Sivagnanam S, Betts CB, Chen HC, Liu Q, Lowe C, Chen H, Boyd KL, Kopparapu PR, Yan Y, Coussens LM, Quaranta V, Tyson DR, Iams W, Lovly CM. Thomas PL, et al. J Thorac Oncol. 2021 Jul;16(7):1211-1223. doi: 10.1016/j.jtho.2021.03.011. Epub 2021 Apr 8. J Thorac Oncol. 2021. PMID: 33839362 Free PMC article.
Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer.
Lovly CM, Boyd KL, Gonzalez-Ericsson PI, Lowe CL, Brown HM, Hoffman RD, Sterling BC, Kapp ME, Johnson DB, Kopparapu PR, Iams WT, Warren MA, Noto MJ, Rini BI, Jagasia M, Das SR, Balko JM. Lovly CM, et al. medRxiv [Preprint]. 2020 May 1:2020.04.29.20085738. doi: 10.1101/2020.04.29.20085738. medRxiv. 2020. PMID: 32511636 Free PMC article. Preprint.
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM. Axelrod ML, et al. Clin Cancer Res. 2020 Nov 1;26(21):5668-5681. doi: 10.1158/1078-0432.CCR-19-3685. Epub 2020 Aug 21. Clin Cancer Res. 2020. PMID: 32826327 Free PMC article.
Tissue-specific expression of p73 and p63 isoforms in human tissues.
Marshall CB, Beeler JS, Lehmann BD, Gonzalez-Ericsson P, Sanchez V, Sanders ME, Boyd KL, Pietenpol JA. Marshall CB, et al. Cell Death Dis. 2021 Jul 27;12(8):745. doi: 10.1038/s41419-021-04017-8. Cell Death Dis. 2021. PMID: 34315849 Free PMC article.
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL. Sudhan DR, et al. Clin Cancer Res. 2019 Jan 15;25(2):771-783. doi: 10.1158/1078-0432.CCR-18-1131. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274983 Free PMC article.
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA; Translational Breast Cancer Research Consortium. Lehmann BD, et al. Clin Cancer Res. 2020 May 1;26(9):2111-2123. doi: 10.1158/1078-0432.CCR-19-2170. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822498 Free PMC article. Clinical Trial.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Sudhan DR, et al. Cancer Cell. 2020 Feb 10;37(2):183-199.e5. doi: 10.1016/j.ccell.2019.12.013. Epub 2020 Jan 23. Cancer Cell. 2020. PMID: 31978326 Free PMC article.
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. Gonzalez-Ericsson PI, et al. J Pathol. 2020 Apr;250(5):667-684. doi: 10.1002/path.5406. Epub 2020 Apr 9. J Pathol. 2020. PMID: 32129476 Free article. Review.
50 results